Novo Nordisk (NVO): What to Watch Ahead of Q1 2026 Earnings
Key Takeaways
- Novo Nordisk is scheduled to report Q1 2026 results on May 6, 2026, before market open.
- Analysts expect EPS of $0.87, down about 5% year-over-year from Q1 2025's $0.92.
- Consensus revenue forecast stands at approximately $11.35 billion, reflecting pressures from pricing and competition.
- Key focus on GLP-1 drugs like Wegovy and Ozempic, amid U.S. pricing erosion and rival competition.
- Company's full-year 2026 guidance calls for adjusted sales growth of -5% to -13% at constant exchange rates (CER).
- Historical beats on EPS suggest potential for positive surprise, though stock has mixed post-earnings reactions.
Earnings Context and Why It Matters
As investors in the healthcare sector, we often look to companies like Novo Nordisk (NVO) for insights into long-term trends in diabetes and obesity treatments. With Q1 2026 earnings set for May 6, the company faces increased attention given its challenging full-year outlook. Management has guided for adjusted sales and operating profit growth of -5% to -13% at CER, pointing to U.S. pricing pressures from drug pricing reforms, patent expiries in select markets, and growing competition in the GLP-1 category from Eli Lilly. This comes after 10% sales growth in 2025, fueled by blockbusters like Ozempic and Wegovy.
From what I see, investors will be particularly focused on updates around volume growth, including the rollout of the new oral Wegovy, and any adjustments to the 2026 guidance. For those holding shares, this report provides a window into how NVO plans to manage these headwinds while tapping into sustained demand for obesity care—a dynamic that could shape sentiment in this volatile space.
Earnings Expectations
Looking at the numbers, analysts forecast consensus EPS of $0.87 for Q1 2026 (January-March), marking a roughly 5% drop from $0.92 in Q1 2025, according to Zacks and MarketBeat data. In DKK terms, Yahoo Finance lists 6.96 DKK per share (3 analysts), a slight increase from 6.53 DKK a year earlier. Revenue consensus sits around $11.35 billion USD, or ~72 billion DKK (12 analysts), which could come in flat to down year-over-year when factoring in forex and pricing effects.
One thing that stands out is Novo Nordisk's history of beating EPS estimates—Q4 2025 came in at $1.01 against $0.90 expected, for instance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Key metrics to watch include sales for Wegovy and Ozempic, which made up ~67% of 2025 revenue; these face U.S. pricing headwinds but could see volume gains from oral formulations. Updates on the 2026 outlook and segment results in Obesity Care and Diabetes will be pivotal, especially CER growth amid forex swings.
Market Reaction and Investor Sentiment
Sentiment remains cautious heading into these results, following February's guidance that sparked a sharp sell-off—shares are down over 30% year-to-date on pricing concerns and competition. Historically, NVO has declined after earnings in 7 of 12 reports, averaging -1.6% on day one, though longer-term reactions have varied. Risks center on shortfalls in GLP-1 volumes or a repeat of the weak guidance; on the flip side, an EPS beat or positive notes on oral Wegovy could drive a rebound. Implied volatility points to a ~7% move already priced in.
Forward Outlook and Key Factors to Monitor
After earnings, attention will turn to how well Novo Nordisk executes against its 2026 guidance of -5% to -13% adjusted sales growth at CER, driven mainly by U.S. pricing reforms and semaglutide patent losses in markets like Brazil and China. The non-adjusted midpoint suggests flat sales and 11% operating profit growth, aided by one-offs.
I'm watching GLP-1 demand closely: Wegovy volumes, particularly the oral version's initial traction with over 600k prescriptions, set against any Ozempic erosion. Competition from Lilly's Mounjaro/Zepbound stays fierce, as do compounded versions despite FDA measures.
Cost dynamics, such as manufacturing ramp-ups and R&D on next-gen therapies, will influence margins. Upcoming events include Q2 results on August 5, the Capital Markets Day on September 20-21, and pipeline updates on higher-dose Wegovy or new indications. Broader factors like Medicare expansion might help offset pressures if volumes pick up.
Why I Use Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener as an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using technical patterns, fundamentals, trends, volatility, and AI signals—customizable by industry, market cap, indicators, price patterns, and more. This streamlines finding trade ideas, breakouts, or opportunities far faster than manual methods, and I've found it especially useful for sector comparisons like biotech ahead of earnings seasons.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NVO's RSI Oscillator ascends from oversold territory
The RSI Indicator for NVO moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 20 of the 27 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NVO just turned positive on October 08, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in 31 of 52 cases over the following month. The odds of a continued upward trend are 60%.
Following a +1.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 210 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
NVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVO as a result. In 55 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The 50-day moving average for NVO moved below the 200-day moving average on October 01, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The Aroon Indicator for NVO entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.076) is normal, around the industry mean (19.199). P/E Ratio (9.689) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). NVO has a moderately high Dividend Yield (0.046) as compared to the industry average of (0.025). P/S Ratio (3.627) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement